Thaddeus Cromwell Reeder,Mark W. Moore,David K. Lyon,Casey K. Jager,Doug Lorenz,Corey Bloom,Kimberley Shepard
申请号：
US16270022
公开号：
US20200009118A1
申请日:
2019.02.07
申请国别(地区):
US
年份:
2020
代理人:
摘要：
In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine, an ABCG2 inhibitor and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine and an ABCG2 inhibitor.
